Mixed Results for Adjuvant Immunotherapy in High-Risk Cutaneous Squamous Cell Carcinoma
The phase 3 KEYNOTE-630 trial found that adjuvant pembrolizumab did not significantly improve progression-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery and radiation.
Real-World Data Confirms Low-Severity Safety Profile for Lisocabtagene Maraleucel Across Blood Cancer Settings
Real-world data from 877 patients and clinical trial data from 702 patients demonstrate that most cytokine release syndrome and neurological events with lisocabtagene maraleucel occur within 15 days of infusion and are not severe.
University of Colorado Cancer Center Partners with Flatiron Health to Streamline Clinical Trial Data Management
Flatiron Health and University of Colorado Cancer Center launch collaboration to implement Clinical Pipeâ„¢, an advanced EHR-to-EDC connector that streamlines clinical trial data capture.
Five-Year CROWN Trial Data Establishes Lorlatinib as First-line Standard for ALK+ NSCLC
Extended follow-up data from the phase 3 CROWN trial demonstrates superior efficacy of lorlatinib over crizotinib, with median progression-free survival not yet reached at 60.2 months.
Botensilimab and Balstilimab Combination Shows Promise in Sarcoma Treatment
A phase one trial of botensilimab and balstilimab shows promising results in treating sarcomas, particularly angiosarcoma, which typically responds poorly to immunotherapy.
Pembrolizumab Plus Lenvatinib Shows Promise in Progressive Thyroid Cancer
A recent clinical trial evaluated the addition of pembrolizumab to lenvatinib for patients with progressive thyroid cancer resistant to radioactive iodine.